Clinuvel Pharmaceuticals Limited (CLVLF) Comparison with companies in other sectors?

Clinuvel Pharmaceuticals Limited has a share price of 50.12M. You can analyze Clinuvel Pharmaceuticals Limited (CLVLF) competitors across different market sectors through stock heatmaps.

What are CLVLF's NET and operating margins?

Clinuvel Pharmaceuticals Limited (CLVLF) operating margin is around 0.49, and net profit margin is approximately 0.40 as of the latest reports.

In what way does CLVLF's earnings per share (EPS) trend reflect its financial momentum?

Clinuvel Pharmaceuticals Limited (CLVLF) EPS is 0.50 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Clinuvel Pharmaceuticals Limited is 16.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Clinuvel Pharmaceuticals Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Clinuvel Pharmaceuticals Limited like P/E which is 17.27, P/B which is 3.03, and PEG which is 0.69. Compare them with sector averages to evaluate if the stock is priced fairly.

Clinuvel Pharmaceuticals Limited

CLVLF•PNK

Healthcare

Biotechnology

$8.00

$0.00(0.00%)

Fundamental Analysis of Clinuvel Pharmaceuticals Limited (CLVLF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.50

P/E Ratio

16.00

ROE

0.19%

Net Margin

0.40%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$400.99M

Shares OutstandingTotal number of shares issued

$50.12M

Book Value/ShareNet worth per share

$4.02

Revenue/ShareAnnual revenue per share

$1.75

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.5

Net MarginNet income as percentage of revenue

40.41%

Operating MarginOperating income as percentage of revenue

49.39%

ROEReturn on shareholders' equity

18.67%

ROAReturn on total assets

15.42%

ROCEReturn on capital employed

21.15%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.62

Cash/ShareCash and equivalents per share

$3.64

FCF YieldFree cash flow as percentage of market cap

5.15%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.05

Dividend YieldAnnual dividend as percentage of stock price

0.40%

Financial Ratios Analysis data is not available for CLVLFFinancial Ratios Analysis details for CLVLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CLVLFSector Benchmarking details for CLVLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Clinuvel Pharmaceuticals Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Clinuvel Pharmaceuticals Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Clinuvel Pharmaceuticals Limited's unique business strengths and challenges.

Key Financial Metrics for Clinuvel Pharmaceuticals Limited

For Clinuvel Pharmaceuticals Limited, essential financial indicators include EPS 0.50, PE 16.00, and ROE 0.19. These key ratios reveal insights into Clinuvel Pharmaceuticals Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Clinuvel Pharmaceuticals Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Clinuvel Pharmaceuticals Limited

Metrics like Net Margin 40.41% and ROA 15.42% shed light on how well Clinuvel Pharmaceuticals Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Clinuvel Pharmaceuticals Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Clinuvel Pharmaceuticals Limited

Using ratios such as P/B Ratio 3.03 and PEG Ratio 0.69, investors can assess whether Clinuvel Pharmaceuticals Limited is appropriately valued based on its financials and growth potential. These figures, combined with Clinuvel Pharmaceuticals Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Clinuvel Pharmaceuticals Limited

Financial health indicators, such as Debt/Equity Ratio 0.004 and Cash Flow $0.62, provide a snapshot of Clinuvel Pharmaceuticals Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Clinuvel Pharmaceuticals Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Clinuvel Pharmaceuticals Limited

Investing in Clinuvel Pharmaceuticals Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Clinuvel Pharmaceuticals Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;